Please use this identifier to cite or link to this item:
http://hdl.handle.net/2445/124043
Full metadata record
DC Field | Value | Language |
---|---|---|
dc.contributor.author | Briones, Javier | - |
dc.contributor.author | Novelli, Silvana | - |
dc.contributor.author | García-Marco, José A. | - |
dc.contributor.author | Tomás, José F. | - |
dc.contributor.author | Bernal, Teresa | - |
dc.contributor.author | Grande, Carlos | - |
dc.contributor.author | Canales, Miguel A. | - |
dc.contributor.author | Torres, Antonio | - |
dc.contributor.author | Moraleda, José María | - |
dc.contributor.author | Panizo, Carlos Manuel | - |
dc.contributor.author | Jarque, Isidro | - |
dc.contributor.author | Palmero, Francisca | - |
dc.contributor.author | Hernández, Miguel | - |
dc.contributor.author | González Barca, Eva | - |
dc.contributor.author | López, Dulce | - |
dc.contributor.author | Caballero, Dolores | - |
dc.contributor.author | GELTAMO (Grupo Español de Linfomas y Trasplantes de Médula Ósea) | - |
dc.date.accessioned | 2018-07-30T07:56:32Z | - |
dc.date.available | 2018-07-30T07:56:32Z | - |
dc.date.issued | 2014-03 | - |
dc.identifier.issn | 0390-6078 | - |
dc.identifier.uri | http://hdl.handle.net/2445/124043 | - |
dc.description | S'adjunta carta al director publicada al Vol. 99 núm. 7 | - |
dc.description.abstract | Lymphoma patients with persistent disease undergoing autologous transplantation have a very poor prognosis in the rituximab era. The addition of radioimmunotherapy to the conditioning regimen may improve the outcome for these patients. In a prospective, phase 2 study, we evaluated the safety and efficacy of the addition of 90Y-ibritumomab tiuxetan to the conditioning chemotherapy in patients with refractory diffuse large B-cell lymphoma. Thirty patients with induction failure (primary refractory; n=18) or refractory to salvage immunochemotherapy at relapse (n=12) were included in the study. The median age of the patients was 53 years (range, 25-67). All patients were given 90Y-ibritumomab tiuxetan at a fixed dose of 0.4 mCi/kg (maximum dose 32 mCi) 14 days prior to the preparative chemotherapy regimen. Histological examination showed that 22 patients had de novo diffuse large B-cell lymphoma and eight had transformed diffuse large B-cell lymphoma. All patients had persistent disease at the time of transplantation, with 25 patients considered to be chemorefractory. The median time to neutrophil recovery (>500 white blood cells/μL) was 11 days (range, 9-21), while the median time to platelet recovery (>20,000 platelets/μL) was 13 days (range, 11-35). The overall response rate at day +100 was 70% (95% CI, 53.6-86.4) with 60% (95% CI, 42.5-77.5) of patients obtaining a complete response. After a median follow-up of 31 months for alive patients (range, 16-54), the estimated 3-year overall and progression-free survival rates are 63% (95% CI, 48-82) and 61% (95% CI, 45-80), respectively. We conclude that autologous transplantation with conditioning including 90Y-ibritumomab tiuxetan is safe and results in a very high response rate with promising survival in this group of patients with refractory diffuse large B-cell lymphoma with a very poor prognosis. Study registered at European Union Drug Regulating Authorities Clinical Trials (EudraCT) N. 2007-003198-22. | - |
dc.format.extent | 6 p. | - |
dc.format.mimetype | application/pdf | - |
dc.language.iso | eng | - |
dc.publisher | Ferrata Storti Foundation | - |
dc.relation.isformatof | Reproducció del document publicat a: https://doi.org/10.3324/haematol.2014.108308 | - |
dc.relation.ispartof | Haematologica, 2014, vol. 99, num. 3, p. 505-510 | - |
dc.relation.uri | https://doi.org/10.3324/haematol.2014.108308 | - |
dc.rights | (c) Ferrata Storti Foundation, 2014 | - |
dc.source | Articles publicats en revistes (Ciències Clíniques) | - |
dc.subject.classification | Cèl·lules mare | - |
dc.subject.classification | Cèl·lules B | - |
dc.subject.classification | Limfomes | - |
dc.subject.classification | Autotrasplantament | - |
dc.subject.other | Stem cells | - |
dc.subject.other | B cells | - |
dc.subject.other | Lymphomas | - |
dc.subject.other | Autotransplantation | - |
dc.title | Autologous stem cell transplantation after conditioning with yttrium-90 ibritumomab tiuxetan plus BEAM in refractory non-Hodgkin diffuse large B-cell lymphoma: results of a prospective, multicenter, phase II clinical trial | - |
dc.type | info:eu-repo/semantics/article | - |
dc.type | info:eu-repo/semantics/publishedVersion | - |
dc.identifier.idgrec | 638103 | - |
dc.date.updated | 2018-07-30T07:56:32Z | - |
dc.rights.accessRights | info:eu-repo/semantics/openAccess | - |
dc.identifier.pmid | 24162789 | - |
dc.identifier.pmid | 24986878 | - |
Appears in Collections: | Articles publicats en revistes (Ciències Clíniques) Articles publicats en revistes (Institut d'lnvestigació Biomèdica de Bellvitge (IDIBELL)) |
Files in This Item:
File | Description | Size | Format | |
---|---|---|---|---|
638103.pdf | 725.79 kB | Adobe PDF | View/Open | |
638103-letter.pdf | 59.32 kB | Adobe PDF | View/Open |
Items in DSpace are protected by copyright, with all rights reserved, unless otherwise indicated.